Eva Turgonyi

TL;DR: The addition of eplerenone during the acute phase of STEMI was safe and well tolerated and reduced the primary endpoint over a mean 13 months follow-up mostly because of significantly lower BNP/NT-proBNP levels.

TL;DR: Data indicate that biomarkers are evolving into a valuable addendum to the diagnostic and therapeutic armamentarium and may help to tailor heart failure therapy on a single patient basis, considering the specific pathogenesis and prognosis.

TL;DR: In heart failure after acute myocardial infarction, both hypo- and hyperglycemia at the postacute phase identify patients with increased risk of death during long-term follow-up and both proved to be strong predictors of all-cause death.

TL;DR: There are some differences in evidence-based treatment decisions between the three main health services providing care for patients with HF in Germany, demonstrating adherence to guideline recommendations and earlier adoption of these evidence- based treatments across all levels of care might further improve patient care.

TL;DR: Eplerenone effectively reduces PIIINP levels when baseline values were above the median and may limit ECMM formation in post-MI without HF.